GLP-1 SG 10mg
A 31-amino-acid lipidated GLP-1 receptor agonist with three engineered modifications, supplied as 10 mg of sterile lyophilized powder for in vitro laboratory study.
25 in stock
What is Semaglutide?
Semaglutide is a synthetic, lipidated 31-amino-acid GLP-1 receptor agonist. It binds the GLP-1 receptor with high affinity and resists DPP-4 degradation, which makes it the standard long-acting reference agonist in GLP-1 receptor pharmacology.
Research areas where laboratories buy semaglutide for in vitro work include GLP-1R binding and cAMP signaling, beta-cell insulin-secretion assays and rodent metabolic models, along with receptor-selectivity comparisons against dual and triple incretin agonists and structural studies of the GLP-1R complex.
Every lot, independently verified
Compound information
Chemical & structural reference data — specifications, molecular profile and handling.
Semaglutide Mechanism of Action
- Binds the human GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed on pancreatic beta-cells, gastric mucosa, and hypothalamic neurons.
- Activates Gαs-coupled signaling, raising intracellular cyclic AMP (cAMP) and triggering glucose-dependent insulin release from beta-cell models.
- Suppresses glucagon secretion from pancreatic alpha-cells under hyperglycemic conditions in cell-based assays.
- Engages GLP-1R on enteric and vagal neurons in rodent models.
- Engages GLP-1R on hypothalamic and brainstem neurons in animal studies.
- Resists DPP-4 cleavage due to the Aib-8 substitution, preserving N-terminal integrity required for receptor binding.
- Binds reversibly to serum albumin through the C18 fatty-diacid side chain, extending its half-life in preclinical pharmacokinetic studies.
Semaglutide Research Applications
- GLP-1 receptor pharmacology in pancreatic beta-cell lines and HEK293 cells expressing human GLP-1R, where semaglutide serves as the standard long-acting agonist for characterizing binding affinity, EC₅₀ values, and downstream cAMP signaling.
- Comparative receptor-selectivity studies pairing semaglutide against tirzepatide (dual GLP-1R/GIPR) and retatrutide (triple GLP-1R/GIPR/GCGR) to isolate single-receptor contributions in cell-based reporter assays.
- Albumin-binding pharmacokinetic research examining how the C18 fatty-diacid side chain prolongs plasma half-life through reversible serum-albumin association.
- Adipocyte and hepatocyte cell models probing GLP-1R-mediated signaling and lipid-metabolism pathways.
- Structural biology, including cryo-EM studies of semaglutide bound to the GLP-1 receptor deposited in the Protein Data Bank for docking and structure-activity work.
- Mechanistic work probing how the Aib substitution at position 8 confers DPP-4 resistance compared with native GLP-1.
Why Buy Semaglutide from Koi Peptides?
- Every batch of Koi semaglutide is synthesized and lyophilized in the United States, then released against independent third-party laboratory (Freedom Diagnostics Testing) testing.
- Each lot is tested by HPLC for purity, LC-MS for identity confirmation, and screened for endotoxin before release.
- The lot ID is printed on every vial and ties back to a public COA library, so researchers can verify documentation before they buy and after the vial arrives.
- Orders placed before 2 PM CT ship the same business day, and shipping is free on orders over $200.
References
View all 6 references +
- Lau, J., et al. (2015). Discovery of the once-weekly GLP-1 analog semaglutide. J. Medicinal Chemistry, 58(18), 7370–7380. doi.org/10.1021/acs.jmedchem.5b00726
- Deacon, C. F. (2004). Circulation and degradation of GLP-1 and GIP. Regulatory Peptides, 128(2), 117–124. doi.org/10.1016/j.regpep.2004.06.007
- Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. doi.org/10.3389/fendo.2019.00155
- Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. doi.org/10.1016/j.molmet.2019.09.010
- Coskun, T., et al. (2022). LY3437943, a triple GCGR/GIPR/GLP-1R agonist. Cell Metabolism, 34(9), 1234–1247. doi.org/10.1016/j.cmet.2022.07.013
- Zhang, X., et al. (2020). Differential GLP-1R binding and activation by peptide and non-peptide agonists. Molecular Cell, 80(3), 485–500. doi.org/10.1016/j.molcel.2020.09.020
Regulatory Status
Regulatory status — provided for research context.
Regulatory Status
The semaglutide supplied by Koi Peptides is a research-grade reagent synthesized for laboratory research only. It is not formulated, packaged or labeled as a drug, food or cosmetic, and is not authorized for any human or veterinary use.
For laboratory and research use only. Not for human consumption. This product is not a drug, food or cosmetic. It is sold exclusively to qualified researchers and licensed laboratories. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Frequently Asked Questions About Semaglutide
What is semaglutide used for in research?+
What purity is Koi's semaglutide?+
How do I prepare a semaglutide solution?+
What is the CAS number for semaglutide?+
Is semaglutide for human use?+
Does semaglutide come with a Certificate of Analysis?+
How should semaglutide be stored?+
How does semaglutide compare with tirzepatide and retatrutide as a research tool?+
Stock your lab with Koi
Research-grade peptides — made in the USA, third-party tested, with public lot-matched COAs. Shop the catalog, or contact our team with questions.



